JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB

robot
Abstract generation in progress

JPMorgan Chase & Co. significantly reduced its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 87.3% in Q3, selling over 815,000 shares. Despite this reduction, other institutional investors like Paradigm Biocapital and Orbis Allan Gray increased their holdings in the biotech company, which has a market cap of $17.67 billion. Genmab recently missed EPS estimates but analysts maintain a “Moderate Buy” rating with a target price of $39.36.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin